Study Finds 33-Fold Rise in BPC-157 Use Despite Limited Safety Data

Use of the unapproved peptide BPC-157, marketed online for pain relief, injury recovery, muscle growth and athletic performance, has surged despite limited human evidence on its safety or effectiveness. A study of more than 15 million medical records identified 1,039 patients whose doctors documented BPC-157 use, with confirmed new users increasing 33-fold from 2020 to 2026; pain, sports injuries and gastrointestinal conditions were among the reported reasons. The findings likely undercount actual use because BPC-157 lacks a National Drug Code and many clinicians may not ask patients about it. The peptide is often combined with TB-500 in a product pairing known as the “Wolverine stack,” while social-media claims and support from U.S. Health Secretary Robert F. Kennedy Jr. have helped fuel its popularity. An FDA advisory panel voted to permit pharmacy compounding, but the agency has not made a final decision and previously cited safety concerns and insufficient human data in restricting the practice. Researchers and health professionals caution that anecdotal reports of improvement do not establish that BPC-157 works and urge patients to disclose peptide use to their doctors, particularly if they experience mental-health changes or injection-site symptoms.